Development of Metabolic Indicators of Burn Injury: Very Low Density Lipoprotein (VLDL) and Acetoacetate Are Highly Correlated to Severity of Burn Injury in Rats

Citation
Izamis, Maria-Louisa, Korkut Uygun, Nripen S. Sharma, Basak Uygun, Martin L. Yarmush, and Francois Berthiaume. 2012. “Development of Metabolic Indicators of Burn Injury: Very Low Density Lipoprotein (VLDL) and Acetoacetate Are Highly Correlated to Severity of Burn Injury in Rats.” Metabolites 2 (3): 458-478. doi:10.3390/metabo2030458. http://dx.doi.org/10.3390/metabo2030458.

Published Version
doi:10.3390/metabo2030458

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407004

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Development of Metabolic Indicators of Burn Injury: Very Low Density Lipoprotein (VLDL) and Acetoacetate Are Highly Correlated to Severity of Burn Injury in Rats

Maria-Louisa Izamis 1, Korkut Uygun 1, Nripen S. Sharma 1, Basak Uygun 1, Martin L. Yarmush 1,2 and Francois Berthiaume 2,*

1 Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, MA 02114, USA
2 Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA

* Author to whom correspondence should be addressed; E-Mail: fberthia@rci.rutgers.edu; Tel: +1-732-445-4500 (ext. 6217); Fax: +1-732-445-3753.

Received: 9 June 2012; in revised form: 3 July 2012 / Accepted: 4 July 2012 / Published: 16 July 2012

Abstract: Hypermetabolism is a significant sequela to severe trauma such as burns, as well as critical illnesses such as cancer. It persists in parallel to, or beyond, the original pathology for many months as an often-fatal comorbidity. Currently, diagnosis is based solely on clinical observations of increased energy expenditure, severe muscle wasting and progressive organ dysfunction. In order to identify the minimum number of necessary variables, and to develop a rat model of burn injury-induced hypermetabolism, we utilized data mining approaches to identify the metabolic variables that strongly correlate to the severity of injury. A clustering-based algorithm was introduced into a regression model of the extent of burn injury. As a result, a neural network model which employs VLDL and acetoacetate levels was demonstrated to predict the extent of burn injury with 88% accuracy in the rat model. The physiological importance of the identified variables in the context of hypermetabolism, and necessary steps in extension of this preliminary model to a clinically utilizable index of severity of burn injury are outlined.

Keywords: hypermetabolism; metabonomics; flux analysis; cluster analysis; regression; variable selection; burn injury
1. Introduction

Hypermetabolism is a significant consequence of severe trauma such as burns [1], as well as critical illnesses such as cancer [2]. It persists in parallel to, or beyond, the original pathology for many months as an often-fatal comorbidity. Prolonged hypermetabolism is characterized by increased resting energy expenditure and severe muscle wasting due to a negative nitrogen balance. The underlying mechanisms that control the onset and resolution of the hypermetabolic response are unknown. Therefore, current treatments are directed at symptoms which are metabolic, endocrine, and immune in nature.

Increasing nutritional energy delivery and protein intake only partially alleviate the loss of lean body mass [3,4]. Experimental approaches to overcome the deleterious effects of hypermetabolism have been used with varying success, including glutamine and arginine supplementation [5,6]; combinatorial nutritional therapies using a diet high in vitamins, protein, amino acids, and ω-3 fatty acids [7]; peroxisome proliferator activated receptor-α agonists to improve fat oxidation and mitochondrial activity [8]; as well as antioxidant and anti-inflammatory agents [9]. Modulation of insulin action [10], direct insulin therapy [11,12], administration of other anabolic agents [13], as well as β-blockers [14] have also produced significant improvements, but are inherently impractical in the long-term, and in some cases produce undesirable, potentially fatal, side effects [15,16].

Rational design and optimization of nutritional therapies can be achieved by targeting the interconnected metabolic network and regulatory pathways impacted by hypermetabolism [17–21], thereby having a broad impact on the metabolome, and subsequently altering the physiome at the genomic and proteomic levels. Hence an understanding of the connections among individual metabolites and the overall injury physiome is necessary to rationally design metabolic interventions. While the advances in metabolomics and metabonomics are starting to present an ever-increasing amount of data, the capability to quantitatively and accurately predict the metabolic effects of nutritional supplements in order to design the kind of combination therapies that could treat hypermetabolism and other metabolic conditions remains absent.

There are a variety of techniques to extract knowledge from “omics” data. These include pattern identification methods such as clustering and principal component analysis (PCA) typically applied to time-series mRNA microarray data to identify key trendlines [22]; network analysis to identify correlations between genes/metabolites [17]; and marker discovery [23], which utilizes a combination of techniques above to correlate disease with a specific measured variable. Metabonomics in particular focuses on the metabolic analysis of the consequences of a perturbation, such as disease and medication. While metabonomics of toxicity [24] and pharmaceuticals [25] is an emerging field, there are few studies performing rigorous metabolic analyses as a function of extent of injury or disease [23,26].

While there has been some effort to develop analytical mathematical models for hypermetabolism [27,28], predictive models remain absent. There are however efforts to develop such approaches, for instance Flux Balance Analysis (FBA), to identify the metabolic causes of fat accumulation in hepatocytes [29,30]; similar approaches could potentially predict metabolic responses to potential interventions, such as amino acid supplements and hence rationally develop combination therapies in hypermetabolism. However, in vivo hypermetabolism remains a mostly clinical observation, and quantitative measures of hypermetabolism to define the extent of burn injury are necessary for use of optimization-based FBA models.
The objective of this study was to identify sensitive indicators that correlate with the severity of injury and that can be measured from blood samples. For this purpose, we used rat models of cutaneous burn injury of increasing size, and analyzed metabolomic data on postburn day 4. We identified VLDL and acetoacetate in the circulation as being particularly sensitive to the extent of burn injury, and thus could serve as a quantitative measure of the grade of hypermetabolism.

2. Experimental Methods

Briefly, male Sprague–Dawley rats (Charles River Labs) weighing between 270 g and 300 g at time of burn, were subjected to a third degree cutaneous burn injury (i.e., depth of injury spans the entire thickness of the skin) covering 20% of the Total Body Surface Area (TBSA) (dorsal burn only) or 40% TBSA (burn on dorsum and abdomen) by contacting the skin with water at 100 °C. Sham-treated animals were handled identically to the burn groups, except that room temperature water was used. After injury, animals were immediately resuscitated with an intraperitoneal saline injection (20 mL/kg per rat) and allowed to recover in individual cages. Animals were weighed daily and food consumption was monitored. On the third day following the injury, all rats were fasted overnight in preparation for the blood samples to be taken on Day 4 as described in detail elsewhere [21]. Briefly, on day 4, each rat was anesthetized and blood flow through each of the major blood vessels entering the liver (the portal vein, PV, and hepatic artery, HA, USA) were measured using a perivascular ultrasonic flow-probe (Transonic Systems, Ithaca, NY, USA). The sum of flow rates into the liver was assumed to equal the flow rate out of the hepatic veins into the suprahepatic vena cava (SHVC). Following flow rate measurements, blood samples from the hepatic veins and PV were taken, followed by arterial blood. Blood samples were analyzed for blood gases and pH using a Rapidlab Blood Gas Analyzer 865 (Bayer). Standard reagent kits were used to determine plasma glucose (Stanbio No. 1075-825), urea (Stanbio No. 0580), and lactate (Trinity Biotech USA No. 735-10). The ketone bodies acetoacetate and β-hydroxybutyrate were measured enzymatically by following the appearance or disappearance of NADH upon the addition of β-hydroxybutyrate dehydrogenase (Sigma), respectively. Nineteen of the common amino acids (except tryptophan) plus ornithine and ammonia were measured using a Waters HPLC apparatus (Waters Co. Milford, MA, USA). ELISA techniques were used to detect albumin (Sigma) and insulin (Crystal Chem Inc No. INSKR020). Alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin, blood urea nitrogen, and creatinine, HDL, LDL, VLDL, cholesterol and triacylglycerols were measured using a Piccolo Comprehensive Metabolic Panel (Abaxis, Inc., Union City, CA, USA). Finally, the liver was excised and weighed. Fluxes across the liver were subsequently determined as the difference between in- and effluxes, calculated per vessel as the product of metabolic concentration and flow rate normalized to the weight of the liver. Note that early injury markers, such as cytokines and tissue damage, have shown a clear linear trend with increasing burn severity [31,32]; however, we sought variables that were less likely to have a transient response or a response subsequently complicated by sepsis so we only employed metabolic markers still visible 4 days after injury for consideration as indicators of burn injury.
3. Numerical Methods

3.1. Theoretical Aspects

The primary goal of this study was to identify key metabolites that are strongly correlated to the hypermetabolism in the form of a predictive model of the degree of burn injury. However, since metabolic data suffer from the existence of a high degree of correlation [17], a straightforward statistical analysis (e.g., ANOVA), is very limited. Many variables will be identified as correlated to injury because of their own interrelationships. Therefore, a critical issue is to identify the key variables involved, which may be defined as the minimum number of variables that can explain the metabolic response to injury. For the purposes of this work, this problem can equivalently be stated as the identification of the minimum number of variables necessary to construct an accurate model that can predict the degree of injury from metabolic data.

It should be noted that in the absence of a mechanistic description of the effects of injury, empirical mathematical models are necessary, which further increases the problem of complexity as the type of model to be used becomes another variable. Therefore, the problem of constructing an “index of burn injury severity” is a multiobjective problem where the task is to simultaneously: (i) select and train the best mathematical model; (ii) maximize model accuracy by selecting the variables to use; (iii) minimize the number of variables in the model. To achieve this goal, we designed a novel algorithm to identify the metabolites that are most indicative of injury grade, as outlined in Figure 1 and discussed in detail below.

**Figure 1.** The burn-injury indicator identification algorithm.

*Clustering of Dose-Response Patterns.* The first step in the algorithm is clustering in order to group the metabolites responding similarly to increased injury, which serves multiple purposes. Clustering serves as the first step in reducing the problem dimensionality, as all metabolites collected in one group can
be considered to be regulated by the same mechanisms, and ideally can be considered as a single variable (or, a single metabolite can adequately represent all others in the same cluster). Therefore, the number of clusters necessary to represent the data presents an adequate first-guess for the ideal number of variables to capture the entire metabolic response. In addition, since we have obtained dose-response data rather than a simple injury vs. non-injury comparison, clustering also identifies the major patterns observed in response to increasing levels of burn injury, which enables incorporating a physiological interpretation prior to identification of the burn-grade indicators.

A critical issue in clustering is the determination of the number of clusters, either defined directly as a parameter (as in k-means clustering which is employed here) or indirectly (as in hierarchical clustering). We utilized a tandem approach to determine the optimum number of clusters, combining analysis of explained variance (here measured as sums of point-to-centroid distances of all clusters) and the separation of individual clusters (assessed through silhouette analysis) [33]. It should be noted that the tandem use is necessary: in clustering, by definition, as the number of clusters increases, the error of clustering is reduced, until each instance (i.e., patient) itself is a cluster and the error is zero, which obviously is of little value. An alternative criterion to identify a good number of clusters that is commonly employed is the marginal gain of adding a cluster, which often displays “elbows” where the marginal value decreases steeply. However, often there are multiple elbows and so multiple choices of good numbers of clusters. To differentiate between such potential solutions, we employed the silhouette analysis, which is a measure of separation for clusters. Briefly, the silhouette value is a measure of how close each point in one cluster is to points in the neighboring clusters. This measure ranges from +1, indicating points that are very distant from neighboring clusters, through 0, indicating points that are not distinctly in one cluster or another, to −1, indicating points that are probably assigned to the wrong cluster [33]. Combining the marginal value and silhouette methods, it is possible to assess marginal return and mean silhouette values as a function of number of clusters, and identify the number of clusters that simultaneously have a local maxima in their silhouette value and display a decrease in cluster error. This is in essence a visual analysis of the two charts to identify the minimum number of clusters.

Identification of Independent Patterns. Identified patterns reveal the key trends in the dose response. In mRNA analysis, the co-regulated gene expression reveals information regarding genetic control motifs [34]. The situation is more complex in metabonomics, as correlations exist due to a variety of reasons such as simple stoichiometric dependencies [17]. Accordingly, it is necessary to extract the actual number of independent patterns in order to filter out these metabolic correlations that are not of primary interest for this study.

To achieve this purpose, a Singular Value Decomposition (SVD) was performed on the cluster centroids: Briefly, each cluster was expressed as a vector (the cluster median for each level of injury was an entry in the vector), and the vectors were augmented to form a cluster centroid matrix. SVD was performed to identify the number of independent patterns, which can be used to explain the remaining patterns. This is in effect a rank analysis, but direct analysis of singular values enables identification of marginally non-zero singular values, which are likely artifacts of measurement error and/or statistical clustering rather than major patterns in the injury response. The number of distinct singular values that are also non-zero (>10^-2, a heuristically chosen limit) was chosen as the number of independent clusters.
The product of this tandem approach is: (i) identified patterns in the injury response; and (ii) the minimum number of patterns that can explain the entire response, which is interpreted here as equivalent to the minimum number of variables that are necessary to construct an index of injury.

It is worth noting that this two-step hybrid procedure to reduce the problem dimensionality has problem-specific advantages over conventional dimension reduction methods such as PCA or Linear Discriminant Analysis (LDA). PCA is the optimum method for elimination of collinearities present in the data, but is not optimized for class separability, hence will be insensitive to the presence of patterns due to elevated injury. LDA is an elegant and “context sensitive” solution, but assumes linearity, which may or may not be valid in burn injury. The method employed here incorporates a sophisticated model selection process, including nonlinear classifiers such as Artificial Neural Networks.

Pattern Analysis. The analysis of clustering provides several layers of information. The independent pattern analysis performed above provides the ideal number of variables that are necessary to capture the injury response. Detailed analysis of cluster membership may reveal further physiological information; for instance, in this work we used changing cluster membership between the liver inlets (hepatic artery and portal vein) and outlet (vena cava) for any particular metabolite as an indicator of altered liver function due to burn injury.

Variable Elimination and Model Selection. For each model (classifier) type considered, the variable elimination task involves finding an optimum list of variables that maximizes the model’s prediction accuracy. N-fold cross-validation accuracies were used to estimate the real-world accuracy for the trained regression models [35,36]: data are separated into N subsets; model training and validation is performed N-times, and in each run one of the subsets is used only for validation and the rest for model training. N-fold cross validation significantly reduces variability in accuracy estimates due to uneven validation data selections as all data is reused for testing the model accuracy. Multiple repetitions of the n-fold cross validation ensure that the selection process for the subsets does not affect the results.

For a given set of variables, comparison of alternative regression models is a straightforward task that can be based on the cross-validation results. If the number of variables is preset, the variable elimination is also a straightforward, albeit computationally intensive procedure: this problem is a combinatorial-optimization problem, where a set number of variables are chosen to maximize cross validation accuracy. In this work, we employed the variable selection algorithm in WEKA which employs a genetic algorithm to select the best variables to maximize the cross-validation accuracy for each classifier. This was followed by a ranking subroutine (Best-first algorithm in WEKA, a greedy step-climbing algorithm augmented with backtracking facility) which was used to select only the preset number of variables.

However, the number of variables is typically a confounding factor. Briefly, the training accuracy improves in regression as the number of variables/free parameters increases, but this results in overtraining, such that the model is not valid for real data (i.e., the model is not generalizable), hence cross-validation accuracy will decrease after a certain point. The straightforward approach is to evaluate the cross-validation accuracy as a function of the number of variables used in the model, and choose the minimum number of variables that provide a high cross-validated accuracy, but this process is a very computationally intensive task since the variable elimination described above has to be
repeated for each set number of variables, and this process has to be repeated for all possible models. Further, there are often multiple good solutions that have very similar accuracies. Therefore, in choosing the best combination of model, variables, and accuracy, determination of the proper weights of these competing objectives becomes a subjective decision.

By comparison, the number of independent patterns identified as described above, provides a simple criterion that can be determined through an objective and quick process. This approach also avoids issues during selection of the best regression model (i.e., the decision of which model to use for the index of hypermetabolism), since number of variables employed by each model becomes an a priori set quantity that is equal for all tested alternatives.

3.2. Methods

Data Preprocessing. The data per rat include metabolite concentrations of each of the PV, HA, and hepatic veins, and metabolic fluxes across the liver on day 4 post-burn. To eliminate outliers, variables with values beyond the median ± 2 × interquartile range for the group were considered as missing [37]. Since individual rat data are used in the construction of a hypermetabolism index, rats with >30% missing extracellular metabolite measurements were removed from the experimental dataset. Overall, 7 out of 12, 7/12, and 7/13 rat datasets were retained for the sham, 20% and 40% TBSA burn conditions, respectively. The missing values were replaced by the median of the measurements of that group. This resulted in a data matrix of 165 measurements on each of 21 animals.

Analysis. To identify major patterns in the dose response to burn, k-means clustering was performed in MATLAB. The average of each variable was calculated for each burn group (sham, 20%, 40%). Each variable was normalized to [−1 1] interval. The Euclidian distance was used as the clustering performance which provided better silhouette values compared to other distance measures (results not shown). Each clustering was run with >10 replicates and that the cluster means and their membership remained similar was confirmed (results not shown). It was observed that the changes in the cluster centroids were negligible between clustering runs, an indicator that the number of clusters was well chosen and cluster separation achieved was close to ideal. The centroid of each cluster was identified as the dose-response pattern.

Training, cross-validation, and selection of regression models were performed in WEKA data mining software [36]. The analysis was performed on per-rat data. The following classifiers were tested: Linear Regression (LR), normalized gaussian Radial Basis Function Network (RBFN), Neural Network (NN) (multilayer perceptron), Sequential Minimal Optimization algorithm for training a support vector Regression model (SMOR), M5P Decision Tree (M5P-DT), Decision Table (DT), M5 Rules (M5-R). For each method, variable selection was performed as described above. The accuracy of each regression model was then evaluated via five 10-fold cross validations, where all randomizable variables in the model, as well as the partitioning of data into 10 folds, were randomized.

4. Results

Clustering. Analysis of the mean silhouette results demonstrated that increase from four to six cluster increased clusters separation only marginally (2.2%), hence four was chosen as the optimum number
Figure 2. Cluster analysis indicates four distinct patterns present in metabolic profiles: (A) Number of clusters vs. sum distance from cluster centroid. (B) Number of clusters vs. silhouette value. (C) Silhouette values for each metabolite within the four clusters identified; a value of 1 indicates the metabolite profile is identical to the cluster centroid; −1 indicates the metabolite displays a perfect inverse profile.

Figure 3. Identified Clusters. (A–D) Profile of metabolites classified within clusters 1–4. (E–H) Centroids (patterns) for each cluster.
**Table 1.** Variables included in analysis and cluster membership.

| Variable                              | Vessel | Cluster | Sham (median ± IQR) | 20% (median ± IQR) | 40% (median ± IQR) |
|---------------------------------------|--------|---------|---------------------|--------------------|--------------------|
| Arginine                              | HA     | 1       | 110.51 ± 10.239     | 182.13 ± 83.525    | 181.24 ± 14.245    |
| Creatinine (Cre)                      | HA     | 1       | 0.2 ± 0             | 0.2 ± 0.05         | 0.2 ± 0            |
| Cysteine                              | HA     | 1       | 15.76 ± 6.57        | 21.36 ± 0.92       | 25.55 ± 1.524      |
| Fraction of Carboxyhemoglobin (FCOHb)| HA     | 1       | 7.9 ± 0.35          | 8.3 ± 1.5          | 8.5 ± 0.8          |
| Fraction of Methyated hemoglobin (Fmeth) | HA    | 1       | 0 ± 0               | 0 ± 0              | 0 ± 0              |
| Low Density Lipoprotein (LDL)         | HA     | 1       | 18 ± 14             | 22 ± 6             | 38 ± 8.75          |
| Ornithine                             | HA     | 1       | 98.84 ± 22.359      | 117.73 ± 2.414     | 139.78 ± 12.129    |
| Total Bilirubin (TBIL)                | HA     | 1       | 0.3 ± 0.075         | 0.3 ± 0            | 0.3 ± 0.1          |
| Total cholesterol/HDL ratio (TC/H)    | HA     | 1       | 2.1 ± 0.1           | 2.2 ± 0.3          | 2.2 ± 0.05         |
| Arginine                              | PV     | 1       | 113.3 ± 104.288     | 227.17 ± 42.862    | 223.04 ± 5.409     |
| Aspartate Amino Transferase (AST)     | PV     | 1       | 74 ± 16.5           | 83 ± 32.5          | 88 ± 27.5          |
| AST/ALT                               | PV     | 1       | 1.73 ± 0.599        | 1.91 ± 0.82        | 2.1 ± 0.893        |
| Cholesterol                           | PV     | 1       | 56 ± 24.5           | 74.5 ± 21.75       | 79 ± 10            |
| Creatinine (Cre)                      | PV     | 1       | 0.2 ± 0             | 0.2 ± 0.05         | 0.2 ± 0            |
| Cysteine                              | PV     | 1       | 14.89 ± 2.658       | 16.46 ± 1.543      | 16.55 ± 1.155      |
| Fraction of Carboxyhemoglobin (FCOHb)| PV     | 1       | 7.2 ± 0.8           | 8.1 ± 1            | 7.7 ± 0.75         |
| Flow Rate                             | PV     | 1       | 9 ± 9.226           | 20.5 ± 10.2        | 22 ± 6.5           |
| Fraction of Methyated hemoglobin (Fmeth) | PV    | 1       | 0 ± 0               | 0 ± 0.05           | 0 ± 0.1            |
| Isoleucine                            | PV     | 1       | 91.03 ± 34.218      | 100.74 ± 12.663    | 99.65 ± 3.513      |
| Low Density Lipoprotein (LDL)         | PV     | 1       | 17 ± 6              | 30 ± 6             | 42.5 ± 9.5         |
| Leucine                               | PV     | 1       | 243.09 ± 67.215     | 308.18 ± 25.007    | 336.71 ± 23.168    |
| Lysine                                | PV     | 1       | 215.96 ± 92.604     | 234.02 ± 21.353    | 269.19 ± 20.227    |
| Phenylalanine                         | PV     | 1       | 58.35 ± 9.465       | 65.69 ± 4.891      | 66.63 ± 7.422      |
| Total Bilirubin (TBIL)                | PV     | 1       | 0.3 ± 0.05          | 0.3 ± 0.05         | 0.3 ± 0.05         |
| Total cholesterol/HDL ratio (TC/H)    | PV     | 1       | 1.9 ± 0.1           | 2 ± 0.1            | 2.3 ± 0.05         |
| Total CO2                             | PV     | 1       | 20 ± 4.5            | 23 ± 0             | 23 ± 3.5           |
| Threonine                             | PV     | 1       | 175.33 ± 61.707     | 219.96 ± 60.936    | 228.44 ± 50.882    |
| Tyrosine                              | PV     | 1       | 62.95 ± 8.409       | 73.73 ± 6.036      | 78.49 ± 8.038      |
| Valine                                | PV     | 1       | 176.6 ± 62.552      | 206.26 ± 19.143    | 206.03 ± 4.825     |
| Arginine                              | SHVC   | 1       | 62.27 ± 2.077       | 211.01 ± 23.971    | 206.12 ± 37.934    |
| AST/ALT                               | SHVC   | 1       | 2.03 ± 0.786        | 2.41 ± 1.036       | 2.36 ± 0.913       |
| Blood Urea Nitrogen (BUN)             | SHVC   | 1       | 13 ± 2              | 15.5 ± 1.5         | 17.5 ± 2.5         |
| Cholesterol                           | SHVC   | 1       | 49 ± 10             | 55 ± 22            | 74 ± 7             |
| Variable                                      | Vessel     | Cluster | Sham (median ± IQR) | 20% (median ± IQR) | 40% (median ± IQR) |
|-----------------------------------------------|------------|---------|---------------------|--------------------|--------------------|
| Creatinine (Cre)                              | SHVC       | 1       | 0.2 ± 0             | 0.2 ± 0.05         | 0.2 ± 0            |
| Cysteine                                      | SHVC       | 1       | 12.07 ± 0.595       | 16.68 ± 2.042      | 18.37 ± 2.285      |
| Flow Rate                                     | SHVC       | 1       | 9.5 ± 9.255         | 20.9 ± 10.2        | 22.2 ± 6.7         |
| Fraction of Methyalted hemoglobin (Fmethyl)   | SHVC       | 1       | 0.25 ± 0.25         | 0.3 ± 0.15         | 0.3 ± 0.3          |
| Isoleucine                                    | SHVC       | 1       | 79.1 ± 12.184       | 103.88 ± 12.065    | 103.42 ± 8.164     |
| Potassium (K)                                 | SHVC       | 1       | 3.2 ± 0.95          | 4.2 ± 0.95         | 4 ± 1.15           |
| Low Density Lipoprotein (LDL)                 | SHVC       | 1       | 17 ± 10.25          | 23 ± 6             | 36 ± 0             |
| Ornithine                                     | SHVC       | 1       | 77.44 ± 19.421      | 89.36 ± 35.165     | 123.36 ± 14.992    |
| Total Bilirubin (TBIL)                        | SHVC       | 1       | 0.3 ± 0.05          | 0.3 ± 0            | 0.3 ± 0.05         |
| Total cholesterol/HDL ratio (TC/H)            | SHVC       | 1       | 2.05 ± 0.2          | 2.1 ± 0.1          | 2.2 ± 0            |
| Valine                                        | SHVC       | 1       | 121.63 ± 54.408     | 204.83 ± 24.603    | 206.6 ± 21.909     |
| AST/ALT                                       | HA         | 2       | 2 ± 0.752           | 2.48 ± 1.04        | 2.07 ± 0.733       |
| Chloride (Cl)                                 | HA         | 2       | 109 ± 10.5          | 114 ± 19           | 109 ± 10.5         |
| Fraction of Oxyhemoglobin (FO2Hb)            | HA         | 2       | 91.2 ± 4.85         | 91.5 ± 2.15        | 84.8 ± 8.35        |
| Sodium (Na)                                   | HA         | 2       | 143 ± 6             | 153 ± 16.5         | 142 ± 9            |
| Partial pressure of CO2 (pCO2)               | HA         | 2       | 43.95 ± 4.9         | 51.3 ± 12.65       | 46.8 ± 1.4         |
| pH                                            | HA         | 2       | 7.27 ± 0.059        | 7.3 ± 0.034        | 7.27 ± 0.042       |
| Partial Oxygen pressure (PO2)                | HA         | 2       | 106.2 ± 19.85       | 117.3 ± 18.5       | 100.35 ± 35.525    |
| Tyrosine                                      | HA         | 2       | 79.81 ± 17.969      | 88.17 ± 6.785      | 78.64 ± 8.325      |
| Acetoacetate                                  | PV         | 2       | 115.35 ± 115.91     | 134.15 ± 91.278    | 50.81 ± 115.089    |
| Alanine                                       | PV         | 2       | 391.58 ± 10.724     | 452.9 ± 113.48     | 395.22 ± 95.64     |
| Alanine Amino Transferase (ALT)               | PV         | 2       | 42 ± 11             | 46 ± 4.5           | 42 ± 4.5           |
| β-hydroxybutyrate                             | PV         | 2       | 81.41 ± 87.551      | 103.82 ± 64.453    | 88.47 ± 49.107     |
| Blood Urea Nitrogen (BUN)                    | PV         | 2       | 12 ± 5.5            | 16 ± 2.5           | 14 ± 3.5           |
| Fraction of Oxyhemoglobin (FO2Hb)            | PV         | 2       | 73.6 ± 12.4         | 82.7 ± 18.75       | 73.7 ± 15.2        |
| Glucose                                       | PV         | 2       | 143 ± 126.5         | 183 ± 55.5         | 147 ± 48.5         |
| Potassium (K)                                 | PV         | 2       | 3.7 ± 1.25          | 4.1 ± 0.7          | 3.7 ± 0.6          |
| Partial pressure of CO2 (pCO2)               | PV         | 2       | 55.6 ± 3.05         | 60.55 ± 5.5        | 57.5 ± 2.3         |
| pH                                            | PV         | 2       | 7.28 ± 0.01         | 7.3 ± 0.077        | 7.26 ± 0.028       |
| Acetoacetate                                  | SHVC       | 2       | 126.21 ± 27.78      | 126.21 ± 13.89     | 30.96 ± 95.246     |
| Aspartate Amino Transferase (AST)             | SHVC       | 2       | 84 ± 16             | 85 ± 13            | 80 ± 31            |
| Fraction of Oxyhemoglobin (FO2Hb)            | SHVC       | 2       | 23.3 ± 5.55         | 28.7 ± 17.65       | 14.1 ± 14          |
| Leucine                                       | SHVC       | 2       | 218.34 ± 52.758     | 261.92 ± 91.466    | 210.42 ± 147.222   |
| Variable                                      | Vessel | Cluster | Sham (median ± IQR) | 20% (median ± IQR) | 40% (median ± IQR) |
|-----------------------------------------------|--------|---------|---------------------|--------------------|--------------------|
| pH                                            | SHVC   | 2       | 7.29 ± 0.02         | 7.32 ± 0.055       | 7.25 ± 0.021       |
| Partial Oxygen pressure (PO2)                 | SHVC   | 2       | 27.2 ± 0.725        | 41.9 ± 15.6        | 15.1 ± 11.4        |
| Alkaline phosphatase (ALP)                    | HA     | 3       | 192 ± 96.5          | 113 ± 21           | 194 ± 74           |
| Aspartate Amino Transferase (ALT)             | HA     | 3       | 49.5 ± 14.25        | 36 ± 7.5           | 39 ± 11.5          |
| β-hydroxybutyrate                             | HA     | 3       | 183.61 ± 194.894    | 65.45 ± 39.132     | 165.2 ± 104.353    |
| Blood Urea Nitrogen (BUN)                     | HA     | 3       | 12.5 ± 7            | 13 ± 1.5           | 17 ± 4.5           |
| Calcium (Ca)                                  | HA     | 3       | 8.5 ± 1.25          | 7 ± 1              | 8.8 ± 0.85         |
| Cholesterol                                   | HA     | 3       | 56.5 ± 14.75        | 58 ± 13            | 73 ± 21            |
| Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb) | HA | 3 | 0.3 ± 4.45 | 0.2 ± 0.4 | 0.3 ± 7.15 |
| Glutamine                                     | HA     | 3       | 406.45 ± 97.249     | 344.31 ± 47.021    | 414.34 ± 24.774    |
| High Density Lipoprotein (HDL)                | HA     | 3       | 33 ± 5              | 27 ± 18            | 36 ± 6.75          |
| Histidine                                     | HA     | 3       | 65.3 ± 0.404        | 61.03 ± 9.453      | 67.39 ± 8.07       |
| Lactate                                       | HA     | 3       | 0.84 ± 0.944        | 0.58 ± 0.942       | 3.47 ± 1.49        |
| Lysine                                        | HA     | 3       | 220.96 ± 66.163     | 181.93 ± 25.467    | 224.74 ± 13.38     |
| Phenylalanine                                 | HA     | 3       | 65.09 ± 7.564       | 63.2 ± 3.598       | 67.17 ± 1.202      |
| Total CO2                                      | HA     | 3       | 21 ± 1.5            | 19 ± 1.5           | 25 ± 3             |
| Total Protein (TP)                            | HA     | 3       | 5.3 ± 0.5           | 3.7 ± 0.7          | 4.7 ± 0.3          |
| Alkaline phosphatase (ALP)                    | PV     | 3       | 174 ± 69            | 151 ± 33.5         | 184 ± 78           |
| Chloride (Cl)                                 | PV     | 3       | 110 ± 14.5          | 109 ± 13           | 112 ± 7            |
| Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb) | PV | 3 | 19.2 ± 13.25 | 9.2 ± 19.7 | 18.6 ± 15.85 |
| High Density Lipoprotein (HDL)                | PV     | 3       | 36 ± 12             | 33 ± 4.5           | 35.5 ± 2.5         |
| Histidine                                     | PV     | 3       | 140.94 ± 16.226     | 120.93 ± 9.821     | 147.78 ± 19.839    |
| Lactate                                       | PV     | 3       | 1.07 ± 0.095        | 0.68 ± 0.632       | 4.38 ± 1.986       |
| Sodium (Na)                                   | PV     | 3       | 146 ± 6.5           | 146 ± 12.5         | 149 ± 2.5          |
| Ornithine                                     | PV     | 3       | 119.81 ± 4.751      | 107.16 ± 6.154     | 120.82 ± 17.96     |
| Proline                                       | PV     | 3       | 161.22 ± 18.151     | 162.06 ± 8.013     | 171.2 ± 35.127     |
| Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb) | SHVC | 3 | 71.1 ± 6 | 59 ± 15.8 | 80 ± 13.45 |
| High Density Lipoprotein (HDL)                | SHVC   | 3       | 26.5 ± 6            | 24 ± 5             | 33 ± 0             |
| Histidine                                     | SHVC   | 3       | 53.01 ± 9.45        | 52.2 ± 18.937      | 61.6 ± 6.314       |
| Lactate                                       | SHVC   | 3       | 1 ± 0.34            | 0.74 ± 0.141       | 3.81 ± 2.135       |
| Lysine                                        | SHVC   | 3       | 205.05 ± 79.978     | 197.38 ± 80.877    | 210.04 ± 29.84     |
| Sodium (Na)                                   | SHVC   | 3       | 148 ± 7             | 148 ± 12.5         | 149 ± 7.5          |
| Partial pressure of CO2 (pCO2)                | SHVC   | 3       | 55.2 ± 6.9          | 51.3 ± 3.75        | 67.4 ± 7           |
| Variable                                | Vessel | Cluster | Sham (median ± IQR) | 20% (median ± IQR) | 40% (median ± IQR) |
|-----------------------------------------|--------|---------|---------------------|--------------------|--------------------|
| Total CO2                               | SHVC   | 3       | 22 ± 4              | 22 ± 2             | 25 ± 0.75          |
| Tyrosine                                | SHVC   | 3       | 61.88 ± 6.68        | 61.29 ± 9.773      | 68.37 ± 7.3        |
| Acetoacetate                            | HA     | 4       | 116.29 ± 22.819     | 110.34 ± 47.623    | 70.65 ± 31.749     |
| Alanine                                 | HA     | 4       | 348.27 ± 41.954     | 297.32 ± 22.715    | 281.4 ± 33.083     |
| Albumin                                 | HA     | 4       | 1.95 ± 0.175        | 1.2 ± 0.3          | 1.3 ± 0.25         |
| Alanine Amino Transferase (ALT)         | HA     | 4       | 49.5 ± 14.25        | 36 ± 7.5           | 39 ± 11.5          |
| Ammonia                                 | HA     | 4       | 49.7 ± 4.527        | 37.3 ± 4.081       | 23.1 ± 4.616       |
| Asparagine                              | HA     | 4       | 41.98 ± 5.488       | 34.51 ± 3.945      | 32.73 ± 6.58       |
| Aspartate                               | HA     | 4       | 11.83 ± 1.549       | 9.25 ± 5.852       | 10.16 ± 2.637      |
| Hemoglobin (%)                          | HA     | 4       | 12.4 ± 1.35         | 12 ± 2.4           | 10.4 ± 1.05        |
| Flow Rate                               | HA     | 4       | 0.65 ± 0.146        | 0.5 ± 0.069        | 0.5 ± 0.426        |
| Glucose                                 | HA     | 4       | 169 ± 87            | 134 ± 46           | 146.5 ± 16         |
| Glutamate                               | HA     | 4       | 76.85 ± 6.662       | 54.15 ± 19.137     | 46.84 ± 17.453     |
| Glycine                                 | HA     | 4       | 216.75 ± 16.195     | 184.88 ± 25.974    | 163.76 ± 19.223    |
| Hematocrit                              | HA     | 4       | 36 ± 3.5            | 35 ± 7             | 31 ± 3             |
| Isoleucine                              | HA     | 4       | 113.82 ± 47.423     | 112.05 ± 19.396    | 108.01 ± 32.529    |
| Potassium (K)                           | HA     | 4       | 4.25 ± 2.15         | 4.2 ± 1.45         | 3.9 ± 0.75         |
| Leucine                                 | HA     | 4       | 369.7 ± 174.817     | 275.1 ± 32.956     | 285.2 ± 87.999     |
| Methionine                              | HA     | 4       | 52.33 ± 11.417      | 40.59 ± 8.321      | 38.75 ± 9.047      |
| Proline                                 | HA     | 4       | 164.52 ± 9.956      | 147.7 ± 27.492     | 147.69 ± 7.333     |
| Serine                                  | HA     | 4       | 223.83 ± 54.196     | 159.53 ± 12.872    | 169.06 ± 26.87     |
| Triglycerides (TG)                      | HA     | 4       | 62 ± 35.75          | 29 ± 7             | 26 ± 6             |
| Threonine                               | HA     | 4       | 256.03 ± 36.785     | 229.07 ± 41.332    | 202.04 ± 15.094    |
| Valine                                  | HA     | 4       | 234.98 ± 107.828    | 184.35 ± 36.559    | 178.74 ± 33.851    |
| Very low density lipoprotein (VLDL)     | HA     | 4       | 13 ± 0.5            | 6 ± 1              | 5 ± 0.5            |
| Albumin                                 | PV     | 4       | 2 ± 0.275           | 1.3 ± 0.35         | 1.3 ± 0.2          |
| Ammonia                                 | PV     | 4       | 108.65 ± 61.525     | 43.74 ± 33.121     | 72.67 ± 10.709     |
| Asparagine                              | PV     | 4       | 51.08 ± 6.886       | 32.09 ± 3.895      | 31.74 ± 0.837      |
| Aspartate                               | PV     | 4       | 19.18 ± 11.097      | 12.7 ± 1.594       | 12.06 ± 2.288      |
| Calcium (Ca)                            | PV     | 4       | 8.7 ± 2.25          | 8.3 ± 0.55         | 7.9 ± 1.65         |
| Hemoglobin (%)                          | PV     | 4       | 14.6 ± 0.95         | 13 ± 1.75          | 12.8 ± 0.5         |
| Glutamate                               | PV     | 4       | 63.16 ± 13.278      | 42.22 ± 11.148     | 48.44 ± 15.319     |
| Glutamine                               | PV     | 4       | 279.12 ± 59.911     | 253.05 ± 70.109    | 250.29 ± 33.243    |
| Glycine                                 | PV     | 4       | 273.49 ± 48.285     | 222.25 ± 33.939    | 204.59 ± 46.681    |
| Hematocrit                              | PV     | 4       | 43 ± 3.5            | 40 ± 5             | 38 ± 2.5           |
| Methionine                              | PV     | 4       | 44.77 ± 4.889       | 44.17 ± 4.749      | 43.82 ± 3.209      |
| Partial Oxygen pressure (PO2)           | PV     | 4       | 69.9 ± 11.75        | 54.2 ± 8.1         | 62.9 ± 15.65       |
| Serine                                  | PV     | 4       | 202.59 ± 14.805     | 148.88 ± 30.334    | 156.79 ± 14.701    |
| Triglycerides (TG)                      | PV     | 4       | 52 ± 43             | 25.5 ± 11.75       | 23 ± 2             |
Table 1. Cont.

| Variable                                      | Vessel | Cluster | Sham (median ± IQR) | 20% (median ± IQR) | 40% (median ± IQR) |
|-----------------------------------------------|--------|---------|---------------------|-------------------|-------------------|
| Total Protein (TP)                            | PV     | 4       | 5 ± 1.25            | 4.7 ± 0.9         | 4.8 ± 0.85        |
| Very low density lipoprotein (VLDL)           | PV     | 4       | 13 ± 5              | 6 ± 1             | 5 ± 0.5           |
| Alanine                                       | SHVC   | 4       | 246.38 ± 53.891     | 156.72 ± 42.529   | 152.26 ± 14.02    |
| Albumin                                       | SHVC   | 4       | 1.9 ± 0.25          | 1.3 ± 0.25        | 1.2 ± 0.25        |
| Alkaline phosphatase (ALP)                    | SHVC   | 4       | 166 ± 67.5          | 129 ± 21          | 147 ± 82          |
| Alanine Amino Transferease (ALT)              | SHVC   | 4       | 40 ± 15.5           | 38 ± 14           | 37 ± 5.5          |
| Ammonia                                       | SHVC   | 4       | 40.44 ± 2.622       | 21.86 ± 10.951    | 15.01 ± 9.875     |
| Asparagine                                    | SHVC   | 4       | 27.87 ± 1.556       | 20.1 ± 3.165      | 18.34 ± 0.097     |
| Aspartate                                     | SHVC   | 4       | 13.57 ± 1.938       | 10.37 ± 4.932     | 8.47 ± 0.817      |
| β-hydroxybutyrate                              | SHVC   | 4       | 275.69 ± 457.311    | 257.28 ± 244.001  | 223.51 ± 174.944  |
| Calcium (Ca)                                   | SHVC   | 4       | 8.6 ± 2.5           | 7.9 ± 0.3         | 8 ± 1.5           |
| Chloride (Cl)                                  | SHVC   | 4       | 111 ± 14.5          | 110.5 ± 4.75      | 109 ± 11          |
| Hemoglobin (%)                                 | SHVC   | 4       | 12.75 ± 0.875       | 10.7 ± 1.75       | 11.6 ± 0.65       |
| Fraction of Carboxyhemoglobin (FCOhb)         | SHVC   | 4       | 290 ± 73.75         | 130 ± 24          | 176 ± 50          |
| Glucose                                       | SHVC   | 4       | 263 ± 73            | 186 ± 72.5        | 152 ± 36.25       |
| Glutamate                                      | SHVC   | 4       | 76.77 ± 43.277      | 49.62 ± 15.79     | 44.7 ± 19.093     |
| Glutamine                                      | SHVC   | 4       | 299.7 ± 56.737      | 254.82 ± 97.786   | 228.06 ± 93.284   |
| Glycine                                       | SHVC   | 4       | 192.45 ± 57.864     | 148.04 ± 8.773    | 117.74 ± 58.252   |
| Hematocrit                                     | SHVC   | 4       | 37.5 ± 2.5          | 31 ± 5            | 34 ± 1.5          |
| Methionine                                     | SHVC   | 4       | 38.47 ± 1.541       | 32.45 ± 2.444     | 34.55 ± 1.049     |
| Phenylalanine                                  | SHVC   | 4       | 54.68 ± 3.359       | 52.83 ± 15.86     | 49.57 ± 14.92     |
| Proline                                       | SHVC   | 4       | 137.82 ± 37.486     | 115.64 ± 6.032    | 113.16 ± 16.448   |
| Serine                                        | SHVC   | 4       | 166.82 ± 20.803     | 105.99 ± 12.727   | 92.92 ± 42.759    |
| Triglycerides (TG)                             | SHVC   | 4       | 25 ± 28.5           | 20 ± 3            | 20 ± 0            |
| Threonine                                      | SHVC   | 4       | 198.18 ± 20.372     | 186.17 ± 59.461   | 157.26 ± 6.575    |
| Total Protein (TP)                             | SHVC   | 4       | 4.9 ± 1.05          | 4.3 ± 0.45        | 4 ± 0.85          |
| Very low density lipoprotein (VLDL)            | SHVC   | 4       | 9.5 ± 4.5           | 5 ± 0             | 5 ± 0             |

Identification of Major Patterns. While there are four major patterns in the metabolic response to burn, they are not necessarily independent. For instance, clusters 1 and 4 apparently display the inverse of the same response. To identify the number of independent patterns, SVD Analysis was employed. This analysis revealed that two patterns explained 98.6% of the total variability observed, indicating that the remaining two patterns were explainable within a margin of error of <2%. The patterns highest weighted in SVD were clusters #2 and #4. It should be noted that the pattern selection here is based purely on overall trends, unlike the analysis of Yang et al. [34] which identifies critical time points of sudden changes in gene expression. Since the resolution of data for burn injury is limited (i.e., we have only three levels of burn injury), it is not possible to employ a similar method to identify the degree of injury where the post-burn hypermetabolic response kicks in.
Analysis of Cluster Membership. In general there were no strong trends observed in the variables comprising the clusters (Table 2). Cluster 2 had nearly equal membership from all vessels. Cluster 4 had the most variables (68 total). Albumin, asparagine, aspartate, glutamate, methionine, serine, hematocrit, triglycerides and VLDL concentrations systemically (i.e., in all vessels observed) were selected to cluster 4, which displayed a general decreasing response with increasing burn. pH and FO2Hb were in cluster 2, which showed a peak at 20% burn. Lactate had increased systemically and was in cluster 3 with a sharp increase at 40% burn; HDL and histidine also belonged in this cluster systematically, although the sharp increase at maximum burn was not present. LDL and cysteine increased systematically, and were in cluster 3.

Table 2. Cluster membership as a function of vessel/flux.

| Cluster | Hepatic Artery | Portal Vein | Vena Cava | Liver Flux | Total |
|---------|----------------|------------|-----------|------------|-------|
| 1       | 9              | 20         | 15        | 9          | 45    |
| 2       | 8              | 10         | 6         | 8          | 26    |
| 3       | 15             | 9          | 9         | 15         | 36    |
| 4       | 23             | 16         | 25        | 23         | 68    |
| Total   | 55             | 55         | 55        | 5          |       |

To analyze the role of the liver in the dose response to burn injury, the variables that were selected to the same cluster in the liver inlet (PV and HA) but different outlet (SHVC) were identified. FCOHb (HA and PV in cluster 1, SHVC in cluster 4), pCO2 (2/3), ALP (3/4) were the three variables identified.

4.1. Model Selection and Index of Burn Injury Severity

The variable elimination process was performed with each model with the number of variables set at two. The two best models were the M5-Rules and NN, with very similar cross validation accuracies (Table 3). The formula for the index of burn injury severity developed via the NN model is:

\[
\text{Burn} (\%TBSA) = 2.11 \left( \frac{1}{1 + e^{-\left[ -3.08 \text{VLDL} (\text{HA}) - 4.63 \text{Acetoacetate} (\text{SHVC}) - 1.55 \right]}} \right) - 1.0388
\]

Table 3. Comparison of tested models.

| Model   | Average Relative Accuracy | Variable 1        | Variable 2                     |
|---------|---------------------------|-------------------|--------------------------------|
| RBF     | 46.06 ± 4.59              | Ammonia (HA)      | Ornithine (SHVC)               |
| DT      | 70.54 ± 7.83              | Asparagine (SHVC) | ALB (HA)                       |
| M5P-DT  | 72.36 ± 1.03              | ALB (HA)          | Ammonia (HA)                   |
| LR      | 73.28 ± 0.55              | VLDL (HA)         | Acetoacetate (SHVC)            |
| SMOR    | 75.92 ± 2.20              | VLDL (HA)         | Acetoacetate (SHVC)            |
| M5-R    | 87.82 ± 1.31              | VLDL (HA)         | Asparagine (SHVC)              |
| NN      | 87.89 ± 2.79              | VLDL (HA)         | Acetoacetate (SHVC)            |

An interesting observation was that very low density lipoprotein (VLDL) (cluster #4) was a common choice in all the high-accuracy models. The acetoacetate level in the SHVC was the second
selection in the NN model, whereas SHVC asparagine concentration was selected in the M5P-R model. The top two regression models, NN and M5P-R, had nearly identical ~88% cross validation accuracy, which has value as a diagnostic index, but with significant room for improvement.

The effects of using additional variables in the index were evaluated for NN and M5P-R (Table 4). The NN model was selected as the regression model of choice since accuracy increased significantly (23%) with up to 4 variables. By contrast, the accuracy of the M5P-R model was slightly increased with a third variable, but later decreased with addition of variables (it should be noted this is indeed the expected situation with proper cross-validation, which can account for over training; without validation data the accuracy would have increased monotonously with addition of new variables). The predictions of the NN model on a case-by-case basis are displayed in Table 5. However, note that these are the results of training on the full set of data, hence the overall accuracy is significantly higher than it would be expected in an actual application, which is what the cross validation results in Table 3 report.

### Table 4. Effect of number of variables on regression accuracy.

| Method | Measure | 2 Variables | 3 Variables | 4 Variables | 5 Variables |
|--------|---------|-------------|-------------|-------------|-------------|
|        | Average Relative Accuracy | 87.89 ± 2.789 | 89.46 ± 1.379 | 90.69 ± 1.508 | 89.18 ± 1.552 |
| NN     | Selected Variables | VLDL (HA), Acetoacetate (SHVC) | VLDL (HA), Acetoacetate (SHVC), pO2 (SHVC) | VLDL (SHVC), Acetoacetate (SHVC), pO2 (SHVC), CO2 (HA) |
|        | Average Relative Accuracy | 87.82 ± 1.312 | 88.71 ± 0.983 | 87.66 ± 1.398 | 87.11 ± 1.038 |
| M5-R   | Selected Variables | VLDL (HA), Asparagine (SHVC) | Albumin (HA), Asparagine (SHVC), BUN (PV) | VLDL (HA), Acetoacetate (SHVC), Albumin (HA), pCO2(SHVC) |

### Table 5. Predictions of neural network model (Training on all data).

| Instance | Burn % (actual) | Predictions |
|----------|----------------|-------------|
|          | 2 Variable Model (%burn) | 3 Variable Model (%burn) | 4 Variable Model (%burn) | 5 Variable Model (%burn) |
| 1        | 0.132          | 0.324        | 1.35           | 1.271          |
| 2        | −0.281         | −0.373       | −0.423         | −0.320         |
| 3        | 3.003          | 0.109        | 0.05           | −0.195         |
| 4        | −0.614         | 0.415        | −0.632         | −0.52 0a       |
| 5        | 0.309          | −0.713       | −0.011         | −0.013         |
| 6        | −0.416         | −0.213       | −0.451         | −0.635         |
Table 5. Cont.

| Instance | Burn % (actual) | 2 Variable Model (%burn) | 3 Variable Model (%burn) | 4 Variable Model (%burn) | 5 Variable Model (%burn) |
|----------|-----------------|--------------------------|--------------------------|--------------------------|--------------------------|
| 7        | 0               | -0.281                   | 0.079                    | -0.301                   | -0.229                   |
| 8        | 20              | 19.048                   | 19.876                   | 20.654                   | 20.528                   |
| 9        | 20              | 19.048                   | 20.171                   | 18.383                   | 18.014                   |
| 10       | 20              | 19.048                   | 19.585                   | 19.72                    | 19.590                   |
| 11       | 20              | 19.048                   | 19.585                   | 19.72                    | 19.590                   |
| 12       | 20              | 25.415                   | 19.686                   | 19.993                   | 19.715                   |
| 13       | 20              | 19.048                   | 19.510                   | 18.22                    | 17.947                   |
| 14       | 20              | 20.255                   | 20.757                   | 20.651                   | 17.947                   |
| 15       | 40              | 40.709                   | 39.911                   | 39.795                   | 39.246                   |
| 16       | 40              | 40.957                   | 40.268                   | 40.919                   | 40.870                   |
| 17       | 40              | 40.709                   | 40.091                   | 40.045                   | 39.633                   |
| 18       | 40              | 41.238                   | 39.938                   | 39.866                   | 39.709                   |
| 19       | 40              | 41.221                   | 38.822                   | 39.612                   | 39.620                   |
| 20       | 40              | 39.865                   | 39.757                   | 38.984                   | 38.333                   |
| 21       | 40              | 36.667                   | 39.739                   | 39.708                   | 39.546                   |

Relative Absolute Error: 8.49%  2.54%  4.10%  5.04%

Finally, since selection of acetoacetate is highly significant as an indicator of mitochondrial redox potential, we also tested the prediction success when acetoacetate/β-hydroxybutyrate ratio (a commonly used predictor of redox potential) is used [38,39]. Briefly, we repeated the variable selection/training algorithm for the following set: acetoacetate/β-hydroxybutyrate ratio (SHVC), acetoacetate/β-hydroxybutyrate ratio (HA), VLDL (SHVC), pO₂ (SHVC), CO₂ (HA), as well as acetoacetate/β-hydroxybutyrate ratio (SHVC) alone with NN and M5-R models. On its own, the acetoacetate/β-hydroxybutyrate ratio was extremely unsuccessful in predicting %TBSA, (average relative errors of 110.87 ± 7.444 and 110.26 ± 3.063 with NN and M5-R, respectively). Inclusion of other variables marginally improved the results but nowhere near the other results in Table 4: The average relative errors were 76.26 ± 15.887 and 64.55 ± 10.283 for NN and M5-R, respectively.

5. Discussion and Conclusions

The most important finding of this work is the strong correlation between VLDL levels and the extent of burn injury. Prior studies indicate that in burn trauma, VLDL secretion is impaired [40]. This is consistent with our observations that for increasing burn, there was a decrease in systemic VLDL. Interestingly, VLDL, LDL, HDL and TG are four of the relatively few variables that were systemically altered (i.e., belonged in the same cluster independent of the measured blood vessel). However, the model developed here suggests that VLDL is the most preferred variable for building a predictor of severity of burn injury; ahead of other potential metabolic targets such as hyperglycemia which is correlated to insulin resistance [9], alanine/glucose (a systemic cycle for conversion of skeletal muscle to glucose during hypermetabolism), or even glutamine and arginine, which tend to be depleted after...
burn injury [5,41,42]. Of note here is that as clustering analysis shows, other potential variables identified in Table 4 demonstrate altering (i.e., belonging to different clusters based on measured vessel) injury dose-response profiles; therefore, predictions based on VLDL are least likely to be affected by tissue specific variations. Very likely, the fact that VLDL decrease is systemic also renders it a more accurate indicator of hypermetabolism.

The second variable of interest, which was selected commonly for most regression models (including M5P-R with 3 or more variables) is acetoacetate (SHVC), which in the context of burn is most important as the precursor for β-hydroxybutyrate. While ketone bodies are not a subject of intense focus in hypermetabolism, it was previously suggested that the acetoacetate/β-hydroxybutyrate ratio reflects the mitochondrial redox potential in the liver [43,44], and in burn patients, a decrease of plasma acetoacetate to β-hydroxybutyrate ratio indicates mitochondrial dysfunction and correlates with developing multiple organ dysfunction [45]. Our rat data show a significant decrease in acetoacetate in the 40% TBSA burn group (Table 1). β-hydroxybutyrate was also decreased, although to a lesser extent, such that the acetoacetate to β-hydroxybutyrate ratio was decreased as well. In general, the decrease in total ketone bodies is regarded as an indicator of a limitation in oxidative phosphorylation after injury [46]. Concomitantly, other variables linked to mitochondrial activity or respiration, such as venous CO₂, were also selected as additional injury indicators by the Neural Network model. It should be noted however, that the acetoacetate/β-hydroxybutyrate ratio by itself was not a particularly useful indicator of extent of burn injury. Further, replacing acetoacetate by the ratio severely decreased the accuracy achievable, with 100% error range, indicating that since the ratio was unsuccessful both on its own and when replacing acetoacetate concentrations, this reduction in accuracy is likely to be at least partially due to amplification or measurement noise. Note that β-hydroxybutyrate was one of the measurements with highest standard deviations relative to group means.

A third variable that was commonly selected was asparagine. Asparagine/aspartate is one of the cycles that carry amino acids from the muscle tissue to the liver during injury and was previously reported to be altered in rat models of burn injury [47]. While asparagine was able to replace acetoacetate in the M5P-R model, for the NN model that was ultimately more successful and could exceed 90% accuracy acetoacetate proved a better variable to include in the index.

It is worth noting that VLDL (SHVC) is not significantly different between the 20% and 40% burn groups, but is significantly reduced compared to the sham group. It can be argued that the ability to differentiate between sham and burn provided by VLDL complements acetoacetate (SHVC), which is different for the 40% burn group, but similar for the sham and 20% burn groups. The interesting note here is that neither of these variables is simply directly correlated to extent of burn, hence use of multiple variables is necessary. This supports our previous findings [21,48] that there are significantly different responses observed between the 20% and 40% burn groups, either because the response at 20% TBSA is significantly less, or possibly as the 20% group is displaying a switch from hypermetabolism to a healing/normal phase as early as 4 days after burn injury. This response is likely the reason that a nonlinear model, such as the multi-layer perceptron, has higher accuracy than other linear models we tested in this study. This result may also justify why hypermetabolism diagnosis is still best based on clinical observations because this ad hoc method allows the physician to account for the nonlinear behavior based on past experience.
Using the 2-variable minimum identified by clustering, an index of burn injury severity was developed. The cross-validated accuracies of the best regression model, artificial Neural Network, was 88%. We also tested the inclusion of additional variables into the regression model. As displayed in Table 4, the accuracy of the multilayer perceptron model could be increased to up to 91% with the addition of arterial total CO₂ (cluster 3) and venous oxygen (cluster 2). While the NN therefore did not include any variable from cluster 1, since cluster 4 displays the inverse dose-response to cluster 1 very closely, this confirms the previous analysis that 2 clusters are sufficient in capturing most of the metabolic response to increased burn injury.

From an application perspective, VLDL is in the same cluster systemically; hence point of measurement is unlikely to affect results significantly (repetition of 2-variable NN model with SHVC VLDL use led to only one rat in the sham burn group being significantly misclassified as 20% burn animal). Acetoacetate also displays a generally decreasing trend in all vessels. It should be noted that for an actual clinical index, ideally all measured variables will be systemically in the same cluster, as well as practical to measure. Most variables meet the criteria selected in the regression models. It is also likely possible to construct a regression model to predict unsuitable metabolites from more easy-to-measure ones, which we have not investigated here; a proper study of such an approach would require repetition of the experiments with tail-vein blood sample data complementing the HA, PV and SHVC samples to test if these less invasive samples correlate accurately to the data in this work.

To our knowledge this is the first attempt at creating a quantitative index of burn injury severity; however, it is important to realize the limitations in clinical applications. As the animals were not subjected to any intervention following burn injury, there were no potential confounding effects from nutritional supplementation, which may not be the case in human patients. Obviously, differences between rat and human metabolism, as well as effects of age and gender differences on the hypermetabolic response [48], will have to be considered for the development of a clinically applicable index.

These indicators of burn injury may provide insight and clues to new metabolic targets for therapy. In addition, the development of a quantitative score to identify the degree of hypermetabolism can ultimately provide a practical way to measure the patient response to injury and treatment. As the current diagnostic criteria are based purely on clinical observations, patient-to-patient variation in metabolism introduces a significant and undesirable degree of uncertainty in the care of the burn patient that could be avoided by such a quantitative index.

Acknowledgements

This work was supported by the Shriners Hospitals for Children and the National Institutes of Health grants# R00-DK080942 and R01-DK096075.

References

1. Herndon, D.N.; Tompkins, R.G. Support of the metabolic response to burn injury. *Lancet* 2004, 363, 1895–1902.
2. Bosaeus, I. Nutritional support in multimodal therapy for cancer cachexia. *Support. Care Cancer* 2008, 16, 447–451.
3. Hart, D.W.; Wolf, S.E.; Herndon, D.N.; Chinkes, D.L.; Lal, S.O.; Obeng, M.K.; Beauford, R.B.; Mlcak, R.P. Energy expenditure and caloric balance after burn. Increased feeding leads to fat rather than lean mass accretion. *Ann. Surg.* **2002**, 235, 152–161.

4. Patterson, B.W.; Nguyen, T.; Pierre, E.; Herndon, D.N.; Wolfe, R.R. Urea and protein metabolism in burned children: Effect of dietary protein intake. *Metabolism* **1997**, 46, 573–578.

5. Windle, E.M. Glutamine supplementation in critical illness: Evidence, recommendations, and implications for clinical practice in burn care. *J. Burn Care Res.* **2006**, 27, 764–772.

6. Yu, Y.M.; Young, V.R.; Tompkins, R.G.; Burke, J.F. Relationships among arginine, citrulline, ornithine, and leucine kinetics in adult burn patients. *Am. J. Clin. Nutr.* **1995**, 62, 960–968.

7. Jeschke, M.G.; Herndon, D.N.; Ebener, C.; Barrow, R.E.; Jauch, K.-W. Nutritional intervention high in vitamins, protein, amino acids, and omega-3 fatty acids improves protein metabolism during the hypermetabolic state after thermal injury. *Arch. Surg.* **2001**, 136, 1301–1306.

8. Cree, M.G.; Newcomer, B.R.; Herndon, D.N.; Qian, T.; Sun, D.Y.; Morio, B.; Zwetsloot, J.J.; Dohm, G.L.; Fram, R.Y.; Aarsland, A.; *et al.* PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children. *Fed. Am. Soc. Exp. Biol.* **2007**, A839.

9. Cree, M.G.; Wolfe, R.R. Postburn trauma insulin resistance and fat metabolism. *Am. J. Physiol. Endocrinol. Metab.* **2008**, 294, E1–E9.

10. Gore, D.C.; Herndon, D.N.; Wolfe, R.R. Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. *J. Trauma* **2005**, 59, 316–322.

11. Pierre, E.J.; Barrow, R.E.; Hawkins, H.K.; Nguyen, T.T.; Sakurai, Y.; Desai, M.; Wolfe, R.R.; Herndon, D.N. Effects of insulin on wound healing. *J. Trauma* **1998**, 44, 342–345.

12. Van den Berghe, G.; Wouters, P.; Weekers, F.; Verwaest, C.; Bruyninckx, F.; Schetz, M.; Vlasselaers, D.; Ferdinande, P.; Lauwers, P.; Bouillon, R. Intensive insulin therapy in critically ill patients. *N. Engl. J. Med.* **2001**, 345, 1359–1367.

13. Wanek, S.; Wolf, S.E. Metabolic response to injury and role of anabolic hormones. *Curr. Opin. Clin. Nutr. Metab. Care* **2007**, 10, 272–277.

14. Herndon, D.N.; Hart, D.W.; Wolf, S.E.; Chinkes, D.L.; Wolfe, R.R. Reversal of catabolism by beta-blockade after severe burns. *N. Engl. J. Med.* **2001**, 345, 1223–1229.

15. De-Souza, D.A.; Greene, L.J. Pharmacological management after burn injury. *J. Nutr.* **1998**, 128, 797–803.

16. Cioffi, W.G. What's new in burns and metabolism. *J. Am. Coll. Surg.* **2001**, 192, 241–254.

17. Steuer, R. Review: On the analysis and interpretation of correlations in metabolomic data. *Brief. Bioinform.* **2006**, 7, 151–158.

18. Yarmush, D.M.; MacDonald, A.D.; Foy, B.D.; Berthiaume, F.; Tompkins, R.G.; Yarmush, M.L. Cutaneous burn injury alters relative tricarboxylic acid cycle fluxes in rat liver. *J. Burn Care Rehabil.* **1999**, 20, 292–302.

19. Yamaguchi, Y.; Yu, Y.M.; Zupke, C.; Yarmush, D.M.; Berthiaume, F.; Tompkins, R.G.; Yarmush, M.L. Effect of burn injury on glucose and nitrogen metabolism in the liver: Preliminary studies in a perfused liver system. *Surgery* **1997**, 121, 295–303.

20. Chen, C.L.; Fei, Z.; Carter, E.A.; Lu, X.M.; Hu, R.H.; Young, V.R.; Tompkins, R.G.; Yu, Y.M. Metabolic fate of extrahepatic arginine in liver after burn injury. *Metabolism* **2003**, 52, 1232–1239.
21. Izamis, M.L.; Sharma, N.S.; Uygun, B.; Bieganski, R.; Saeidi, N.; Nahmias, Y.; Uygun, K.; Yarmush, M.L.; Berthiaume, F. In situ metabolic flux analysis to quantify the liver metabolic response to experimental burn injury. *Biotechnol. Bioeng.* **2011**, *108*, 839–852.

22. Kaddurah-Daouk, R.; Kristal, B.S.; Weinshilboum, R.M. Metabolomics: A global biochemical approach to drug response and disease. *Annu. Rev. Pharmacol. Toxicol.* **2008**, *48*, 653–683.

23. Beger, R.; Holland, R.; Sun, J.; Schnackenberg, L.; Moore, P.; Dent, C.; Devarajan, P.; Portilla, D. Metabonomics of acute kidney injury in children after cardiac surgery. *Pediatr. Nephrol.* **2008**, *23*, 977–984.

24. Keun, H.C.; Athersuch, T.J. Application of metabonomics in drug development. *Pharmacogenomics* **2007**, *8*, 731–741.

25. Clayton, A.T.; Lindon, J.C.; Cloarec, O.; Antti, H.; Charuel, C.; Hanton, G.; Provost, J.-P.; Le Net, J.-L.c.; Baker, D.; Walley, R.J.; *et al.* Pharmaco-metabonomic phenotyping and personalized drug treatment. *Nature* **2006**, *440*, 1073–1077.

26. Erb, G.; Elbayed, K.; Piotto, M.; Raya, J.; Neuville, A.; Mohr, M.; Maitrot, D.; Kehrli, P.; Namer, I.J. Toward improved grading of malignancy in oligodendrogliomas using metabolomics. *Magn. Reson. Med.* **2008**, *59*, 959–965.

27. Banta, S.; Vemula, M.; Yokoyama, T.; Jayaraman, A.; Berthiaume, F.; Yarmush, M.L. Contribution of gene expression to metabolic fluxes in hypermetabolic livers induced through burn injury and cecal ligation and puncture in rats. *Biotechnol. Bioeng.* **2007**, *97*, 118–137.

28. Banta, S.; Yokoyama, T.; Berthiaume, F.; Yarmush, M.L. Quantitative effects of thermal injury and insulin on the metabolism of the skeletal muscle using the perfused rat hindquarter preparation. *Biotechnol. Bioeng.* **2004**, *88*, 613–629.

29. Uygun, K.; Matthew, H.W.T.; Huang, Y.L. DFBA-LQR: An optimal control approach to flux balance analysis. *Ind. Eng. Chem. Res.* **2006**, *45*, 8554–8564.

30. Uygun, K.; Matthew, H.W.T.; Huang, Y. Investigation of metabolic objectives in cultured hepatocytes. *Biotechnol. Bioeng.* **2007**, *97*, 622–637.

31. Barber, R.C.; Maass, D.L.; White, J.; Horton, J.W. Increasing percent burn is correlated with increasing inflammation in an adult rodent model. *Shock* **2008**, *30*, 388–393.

32. Barrow, R.E.; Meyer, N.A.; Jeschke, M.G. Effect of varying burn sizes and ambient temperature on the hypermetabolic rate in thermally injured rats. *J. Surg. Res.* **2001**, *99*, 253–257.

33. Kaufman, L.; Rousseeuw, P. *Finding Groups in Data: An Introduction to Cluster Analysis*; Wiley: New York, NY, USA, 1990.

34. Yang, E.; Maguire, T.; Yarmush, M.L.; Berthiaume, F.; Androulakis, I.P. Bioinformatics analysis of the early inflammatory response in a rat thermal injury model. *BMC Bioinform.* **2007**, *8*, 10.

35. Picard, R.R.; Cook, R.D. Cross-validation of regression-models. *J. Am. Stat. Assoc.* **1984**, *79*, 575–583.

36. Witten, I.H.; Frank, E. *Data Mining: Practical Machine Learning Tools and Techniques*, 2nd ed.; Morgan Kaufmann: San Francisco, CA, USA, 2005.

37. Tukey, J.W. *Exploratory Data Analysis*; Addison-Wesley: Reading, MA, USA, 1977.

38. Laun, R.A.; Rapsch, B.; Abel, W.; Schroder, O.; Roher, H.D.; Ekkernkamp, A.; Schulte, K.M. The determination of ketone bodies: Preanalytical, analytical and physiological considerations. *Clin. Exp. Med.* **2001**, *1*, 201–209.
39. Oda, S.; Hirasawa, H.; Sugai, T.; Shiga, H.; Matsuda, K.; Ueno, H. Cellular injury score for multiple organ failure severity scoring system. *J. Trauma* 1998, 45, 304–310; discussion 310–311.

40. Martini, W.Z.; Irtun, O.; Chinkes, D.L.; Rasmussen, B.; Traber, D.L.; Wolfe, R.R. Alteration of hepatic fatty acid metabolism after burn injury in pigs. *JPEN J. Parenter. Enteral Nutr.* 2001, 25, 310–316.

41. Yu, Y.-M.; Young, V.R.; Castillo, L.; Chapman, T.E.; Tompkins, R.G.; Ryan, C.M.; Burke, J.F. Plasma arginine and leucine kinetics and urea production rates in burn patients. *Metabolism* 1995, 44, 659–666.

42. Yu, Y.M.; Ryan, C.M.; Castillo, L.; Lu, X.M.; Beaumier, L.; Tompkins, R.G.; Young, V.R. Arginine and ornithine kinetics in severely burned patients: increased rate of arginine disposal. *Am. J. Physiol. Endocrinol. Metab.* 2001, 280, E509–E517.

43. Nakatani, T.; Spolter, L.; Kobayashi, K. Arterial ketone body ratio as a parameter of hepatic mitochondrial redox state during and after hemorrhagic shock. *World J. Surg.* 1995, 19, 592–596.

44. Ozawa, K.; Mori, K.; Morimoto, T. Evaluation of hepatic function. *Curr. Opin. Gen. Surg.* 1994, 17–23.

45. Dong, Y.L.; Sheng, C.Y.; Herndon, D.N.; Waymack, J.P. Metabolic abnormalities of mitochondrial redox potential in postburn multiple system organ failure. *Burns* 1992, 18, 283–286.

46. Gore, D.C.; Rinehart, A.; Asimakis, G. Temporal changes in cellular energy following burn injury. *Burns* 2005, 31, 998–1002.

47. Banta, S.; Yokoyama, T.; Berthiaume, F.; Yarmush, M.L. Effects of dehydroepiandrosterone administration on rat hepatic metabolism following thermal injury. *J. Surg. Res.* 2005, 127, 93–105.

48. Izamis, M.; Uygur, K.; Uygur, B.; Yarmush, M.; Berthiaume, F. Effects of burn injury on markers of hypermetabolism in rats. *J. Burn Care Res.* 2009, 30, 993–1001.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).